Re: RESEARCH - Vaccination in patients with chronic rheumatic or autoimmune diseases

[Guest guest]

This seems like counter-research then:

http://www.ncbi.nlm.nih.gov/pubmed/14978666?ordinalpos=1 & itool=EntrezSystem2.PEn\

trez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_Discovery_RA & linkpo\

s=2 & log$=relatedarticles & logdbfrom=pubmed

The effect of tumor necrosis factor blockade on the response to pneumococcal

vaccination in patients with rheumatoid arthritis and ankylosing spondylitis.

Elkayam O, Caspi D, Reitblatt T, Charboneau D, Rubins JB.

Department of Rheumatology, Tel Aviv Sourasky Medical Center, Israel.

oribe14@...

OBJECTIVE: To assess the effect of anti-tumor necrosis factor (TNF) alpha

therapies on the immunogenicity of pneumococcal vaccination in patients with

rheumatoid arthritis (RA) and ankylosing spondylitis (AS). METHODS: A group of

16 consecutive patients (11 with RA and 5 with AS) treated either with

infliximab or etanercept, and a control group of 17 age-matched RA patients

treated with disease-modifying medications other than anti-TNF-alpha, received

intradeltoid injection with 0.5 mL of pneumococcal vaccine. Pneumococcal

polysaccharide (PPS)-specific IgG to 7 vaccine PPS (representing high- and

low-prevalence serotypes) was measured by enzyme-linked immunosorbent assay in

sera obtained before and 1 month after pneumococcal immunization. RESULTS: One

month after vaccination, both groups had significant increases in the geometric

mean concentration of capsule PPS-specific antibody and in the mean fold

increase in antibody levels to all 7 serotypes, compared with prevaccination

levels. However, compared with the control group, the TNF-alpha blockade-treated

patients tended to have lower antibody increases for all the serotypes tested

except serotype 14. In addition, lower proportions of TNF-alpha blockade-treated

patients responded to pneumococcal vaccination compared with patients on other

therapies. Similarly, more TNF-alpha blockade-treated patients were poor

responders compared with patients not on anti-TNF-alpha treatment.

CONCLUSION: Treatment of groups of patients with etanercept or infliximab does

not impair their mean antibody responses to pneumococcal vaccination. However, a

larger proportion of RA patients may not respond adequately to pneumococcal

vaccination once on TNF-alpha blockade therapies. *******Consequently,

pneumococcal vaccination before starting TNF-alpha blockade therapy is

recommended.

PMID: 14978666 [PubMed - indexed for MEDLINE]

[Guest guest]

I'm not sure what you mean, OKD.

Not an MD

On Fri, Sep 18, 2009 at 12:09 PM, OKD <Cofade_2000@...> wrote:

> This seems like counter-research then:

>

>

http://www.ncbi.nlm.nih.gov/pubmed/14978666?ordinalpos=1 & itool=EntrezSystem2.PEn\

trez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_Discovery_RA & linkpo\

s=2 & log$=relatedarticles & logdbfrom=pubmed

>

> The effect of tumor necrosis factor blockade on the response to pneumococcal

vaccination in patients with rheumatoid arthritis and ankylosing spondylitis.

>

> Elkayam O, Caspi D, Reitblatt T, Charboneau D, Rubins JB.

> Department of Rheumatology, Tel Aviv Sourasky Medical Center, Israel.

oribe14@...

>

> OBJECTIVE: To assess the effect of anti-tumor necrosis factor (TNF) alpha

therapies on the immunogenicity of pneumococcal vaccination in patients with

rheumatoid arthritis (RA) and ankylosing spondylitis (AS). METHODS: A group of

16 consecutive patients (11 with RA and 5 with AS) treated either with

infliximab or etanercept, and a control group of 17 age-matched RA patients

treated with disease-modifying medications other than anti-TNF-alpha, received

intradeltoid injection with 0.5 mL of pneumococcal vaccine. Pneumococcal

polysaccharide (PPS)-specific IgG to 7 vaccine PPS (representing high- and

low-prevalence serotypes) was measured by enzyme-linked immunosorbent assay in

sera obtained before and 1 month after pneumococcal immunization. RESULTS: One

month after vaccination, both groups had significant increases in the geometric

mean concentration of capsule PPS-specific antibody and in the mean fold

increase in antibody levels to all 7 serotypes, compared with prevaccination

levels. However, compared with the control group, the TNF-alpha blockade-treated

patients tended to have lower antibody increases for all the serotypes tested

except serotype 14. In addition, lower proportions of TNF-alpha blockade-treated

patients responded to pneumococcal vaccination compared with patients on other

therapies. Similarly, more TNF-alpha blockade-treated patients were poor

responders compared with patients not on anti-TNF-alpha treatment.

>

> CONCLUSION: Treatment of groups of patients with etanercept or infliximab does

not impair their mean antibody responses to pneumococcal vaccination. However, a

larger proportion of RA patients may not respond adequately to pneumococcal

vaccination once on TNF-alpha blockade therapies. *******Consequently,

pneumococcal vaccination before starting TNF-alpha blockade therapy is

recommended.

>

> PMID: 14978666 [PubMed - indexed for MEDLINE]

[Guest guest]

>

> This seems like counter-research then:

>

>

http://www.ncbi.nlm.nih.gov/pubmed/14978666?ordinalpos=1 & itool=EntrezSystem2.PEn\

trez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_Discovery_RA & linkpo\

s=2 & log$=relatedarticles & logdbfrom=pubmed

>

> The effect of tumor necrosis factor blockade on the response to pneumococcal

vaccination in patients with rheumatoid arthritis and ankylosing spondylitis.

>

> Elkayam O, Caspi D, Reitblatt T, Charboneau D, Rubins JB.

> Department of Rheumatology, Tel Aviv Sourasky Medical Center, Israel.

oribe14@...

>

> OBJECTIVE: To assess the effect of anti-tumor necrosis factor (TNF) alpha

therapies on the immunogenicity of pneumococcal vaccination in patients with

rheumatoid arthritis (RA) and ankylosing spondylitis (AS). METHODS: A group of

16 consecutive patients (11 with RA and 5 with AS) treated either with

infliximab or etanercept, and a control group of 17 age-matched RA patients

treated with disease-modifying medications other than anti-TNF-alpha, received

intradeltoid injection with 0.5 mL of pneumococcal vaccine. Pneumococcal

polysaccharide (PPS)-specific IgG to 7 vaccine PPS (representing high- and

low-prevalence serotypes) was measured by enzyme-linked immunosorbent assay in

sera obtained before and 1 month after pneumococcal immunization. RESULTS: One

month after vaccination, both groups had significant increases in the geometric

mean concentration of capsule PPS-specific antibody and in the mean fold

increase in antibody levels to all 7 serotypes, compared with prevaccination

levels. However, compared with the control group, the TNF-alpha blockade-treated

patients tended to have lower antibody increases for all the serotypes tested

except serotype 14. In addition, lower proportions of TNF-alpha blockade-treated

patients responded to pneumococcal vaccination compared with patients on other

therapies. Similarly, more TNF-alpha blockade-treated patients were poor

responders compared with patients not on anti-TNF-alpha treatment.

>

> CONCLUSION: Treatment of groups of patients with etanercept or infliximab does

not impair their mean antibody responses to pneumococcal vaccination. However, a

larger proportion of RA patients may not respond adequately to pneumococcal

vaccination once on TNF-alpha blockade therapies. *******Consequently,

pneumococcal vaccination before starting TNF-alpha blockade therapy is

recommended.

>

> PMID: 14978666 [PubMed - indexed for MEDLINE]

>

[Guest guest]

Researchers contradict each other is what I mean.

OKD